
Bayer Consumer Health leaders propose new principles for science-led self-care
Empowering consumers to take more control over their own health means ensuring they have the knowledge and trust that products are safe and will work…
Empowering consumers to take more control over their own health means ensuring they have the knowledge and trust that products are safe and will work…
IMscin001 study showed non-inferior levels of cancer immunotherapy Tecentriq in the blood, when injected subcutaneously, compared to intravenous infusion, in people with advanced non-small cell lung cancer…
GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission’s (EC) Health Emergency Preparedness and Response Authority (HERA) for the…
Investment delivers on Bayer’s commitments to sustainability and may help decarbonize agriculture and reduce reliance on nitrogen fertilizer with combined expertise of existing investors, Bunge…
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to evaluate…
Based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu is the first HER2-directed therapy to demonstrate a survival benefit in this population Application…
Submission of proposed biosimilar supported by comprehensive package; aims to expand treatment access for people with multiple sclerosis in US and EU Multiple sclerosis (MS)…
First and only biologic recommended for EU approval in patients with severe asthmawith no phenotype or biomarker limitations AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation…
Vabysmo (faricimab) simultaneously targets and inhibits two disease pathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) The CHMP recommendation is based…
– Tecartus ® (Brexucabtagene Autoleucel) First and Only CAR T in Europe to Receive Positive CHMP Opinion to Treat Adults 26+ with r/r ALL – – If Approved, it will Address…
Approval recommended for first-line treatment of advanced melanoma patients with tumor cell PD-L1 expression < 1% Recommendation based on results from the Phase 2/3 RELATIVITY-047…
AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory…